Souvik Chattopadhyay serves as the Director of Biology at Pearl Bio, where he leverages over 12 years of post-PhD experience in the bio-pharmaceutical sector, particularly in antibody and antibody-drug conjugate (ADC) discovery and drug development. His extensive expertise encompasses a wide range of critical areas,...
Souvik Chattopadhyay serves as the Director of Biology at Pearl Bio, where he leverages over 12 years of post-PhD experience in the bio-pharmaceutical sector, particularly in antibody and antibody-drug conjugate (ADC) discovery and drug development. His extensive expertise encompasses a wide range of critical areas, including antibody discovery, molecular biology, and biologics production. In his role, Souvik leads multiple protein therapeutics programs, overseeing projects from initial discovery phases through to lead molecule selection and IND filings for large pharmaceutical partners.
A key aspect of Souvik's work involves the integration of advanced techniques in protein engineering and in vitro and in vivo biology, ensuring that drug candidates are not only effective but also safe for clinical use. His proficiency in molecular cloning, transfection, and signal transduction allows him to navigate the complexities of cancer research, utilizing animal models and confocal microscopy to validate therapeutic efficacy.
Souvik's leadership in project management has been instrumental in delivering innovative solutions that meet the evolving needs of the industry. He is adept at fostering collaboration across multidisciplinary teams, facilitating the seamless transition of projects from the laboratory to clinical development. His commitment to advancing cancer therapeutics positions him as a pivotal figure in the bio-pharmaceutical landscape, driving forward the discovery of next-generation biologics that hold the potential to transform patient care.
